Melanoma trials in United States

In United States 268 Also abroad 578

268 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Where
Aurora, Houston, Lake Mary, Lebanon, Providence
Age
18 years and over
People
126
Run by
7 Hills Pharma, LLC
See details and how to joinNCT06362369
Phase 1Taking people
A Study of VET3-TGI in Patients With Solid Tumors
Where
Dallas, Houston, Indianapolis, Los Angeles, Miami, Orange, Pittsburgh
Age
18 years and over
People
60
Run by
KaliVir Immunotherapeutics
See details and how to joinNCT06444815
Phase 2Not yet taking people in United States
PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
Where
Houston
Age
18 years and over
People
20
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT07511036
Phase 2/3Taking people
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Where
Atlanta, Aurora, Boston, Chicago, Columbus, Dallas, Durham, Englewood, Germantown, Houston, Iowa City, Jacksonville, Knoxville, La Jolla, Los Angeles, Madison, Miami, Nashville, New York, Palo Alto, Philadelphia, Pittsburgh, Rochester, Scottsdale, Seattle, Washington D.C.
Age
18 years and over
People
280 worldwide
Run by
Replimune, Inc.
See details and how to joinNCT06581406 · EU 2023-508784-68-00
Phase 2Taking people
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Where
Tampa
Age
18 years and over
People
90
Run by
H. Lee Moffitt Cancer Center and Research Institute
See details and how to joinNCT06295159
Phase 2Taking people
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Where
Tampa
Age
18 years and over
People
18
Run by
H. Lee Moffitt Cancer Center and Research Institute
See details and how to joinNCT07276386
Phase 2Not yet taking people in United States
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
Where
Hackensack
Age
18 years and over
People
65
Run by
Rapa Therapeutics LLC
See details and how to joinNCT06708455
Phase 1Taking people
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Where
Duarte, Los Angeles, Stanford
Age
18 years to 75 years
People
18
Run by
Anusha Kalbasi
See details and how to joinNCT04119024
Phase 2Taking people
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Where
Columbus
Age
18 years to 99 years
People
100
Run by
Ohio State University Comprehensive Cancer Center
See details and how to joinNCT06223659
Phase 2Taking people
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
Where
Orange
Age
18 years and over
People
14
Run by
University of California, Irvine
See details and how to joinNCT06771544
Phase 1/2Taking people
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Where
Dallas, Farmington Hills, Indianapolis, La Jolla, San Antonio
Age
18 years and over
People
180 worldwide
Run by
Hummingbird Bioscience
See details and how to joinNCT06956690
No phaseTaking people
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
Where
Cincinnati
Age
18 years and over
People
21
Run by
Jordan Kharofa
See details and how to joinNCT07225036
Phase 3Taking people
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Where
Atlanta, Boston, Columbus, Edgewood, Houston, Jacksonville, Knoxville, Lake Success, Minneapolis, New Brunswick, New York, Oklahoma City, Orlando, Philadelphia, Phoenix, Pittsburgh, Rochester, Salt Lake City, Seattle, Spartanburg, St Louis, Westwood
Age
18 years and over
People
540 worldwide
Run by
Immunocore Ltd
See details and how to joinNCT05549297 · EU 2022-502732-39-00
Phase 3Taking people
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Where
Aurora, Boston, Charlottesville, Chicago, Columbus, Dallas, Denver, Detroit, Edgewood, Farmington, Greenville, Hackensack, Jacksonville, Knoxville, La Jolla, Lake Success, Los Angeles, Miami, Minneapolis, Nashville, New York, Palo Alto, Philadelphia, Pittsburgh, Richmond, Salt Lake City, Santa Monica, Seattle, Spartanburg, St Louis, Tucson, Washington D.C., Westwood
Age
18 years and over
People
680 worldwide
Run by
Immunocore Ltd
See details and how to joinNCT06112314
Phase 2Taking people
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Where
Miami
Age
18 years and over
People
30
Run by
University of Miami
See details and how to joinNCT06627244
No phaseTaking people
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Where
St Louis
Age
18 years and over
People
100
Run by
Washington University School of Medicine
See details and how to joinNCT04354064
Phase 2Taking people
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
Where
Harrison, New York
Age
18 years and over
People
20
Run by
Memorial Sloan Kettering Cancer Center
See details and how to joinNCT05384496
No phaseTaking people
A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
Where
Columbus
People
1,000
Run by
Ohio State University Comprehensive Cancer Center
See details and how to joinNCT04567706
Phase 1Taking people
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
Where
Easton, Iowa City, Lexington, Nashville
Age
18 years and over
People
30
Run by
Rina Plattner
See details and how to joinNCT04903119
No phaseTaking people
Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically
Where
Lebanon
Age
18 years and over
People
125
Run by
Dartmouth-Hitchcock Medical Center
See details and how to joinNCT07201376
Phase 1Taking people
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
Where
Charlotte, Durham, Greenville, Washington D.C.
Age
18 years and over
People
52
Run by
Immunolight, LLC
See details and how to joinNCT04389281
No phaseTaking people
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
Where
Pittsburgh
Age
18 years and over
People
30
Run by
John Kirkwood
See details and how to joinNCT06599619
Phase 1Taking people
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Where
Dallas, Fairfax, Huntersville
Age
18 years and over
People
270
Run by
Conjupro Biotherapeutics, Inc.
See details and how to joinNCT07317505
No phaseTaking people
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
Where
Madison
Age
18 years and over
People
24
Run by
University of Wisconsin, Madison
See details and how to joinNCT06199713
No phaseTaking people
Sample Collection for Ongoing Research and Product Evaluation Study
Where
Austin
Age
18 years and over
People
9,600
Run by
Natera, Inc.
See details and how to joinNCT07318051